NDC 54771-9050-1 - Telazol
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 54771-9050
- Requested NDC
- 54771-9050-1
- Package NDCs from labels
- 54771-9050-1
- Manufacturer
- Zoetis Inc.
- Effective date
- 2023-09-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Telazol ® CIII (tiletamine and zolazepam for injection) | Zoetis Inc. | 2023-09-11 | PRESCRIPTION ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54771-9050-1 | Telazol | 1 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 1 | 6 | |
| 54771-9050-1 | Telazol | 5 mL in 1 BOTTLE | INJECTION, POWDER, FOR SOLUTION | 5 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54771-9050 | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 6 | 2 package rows | 20230912_3ef51363-2236-40aa-bf32-601c9f1c722a.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| tiletamine hydrochloride | ACTIVE INGREDIENT | 99TAQ2QWJI | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 2 | |
| zolazepam hydrochloride | ACTIVE INGREDIENT | 45SJ093Q1N | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 2 | |
| tiletamine | ACTIVE MOIETY | 2YFC543249 | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 2 | |
| zolazepam | ACTIVE MOIETY | G1R474U58U | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 2 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | TELAZOL (TILETAMINE HYDROCHLORIDE AND ZOLAZEPAM HYDROCHLORIDE) INJECTION, POWDER, FOR SOLUTION [ZOETIS INC.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | 3OWL53L36A |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 8f8f53e3-fe31-e7b5-e053-2995a90a710d | 2025-11-14 | Warnings | 3OWL53L36A |
| QR PAIN | ANALGESIC | MARYHELENE ENTERPRISES INC | 9984a510-30be-4013-e053-2995a90a841e | 2025-11-14 | Warnings | 3OWL53L36A |
| Mannitol | MANNITOL | ProPharma Distribution | 430669d7-9ad1-9a04-e063-6394a90ababb | 2025-11-07 | Warnings, Adverse reactions | 3OWL53L36A |
| Sorbitol-Mannitol | SORBITOL AND MANNITOL | ICU Medical Inc. | 5b44e248-4b7b-4777-954a-921c7b309944 | 2025-10-30 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | ICU Medical Inc. | ba7bf864-8a4d-4262-8fd1-00174fa2f9d1 | 2025-10-24 | Warnings, Adverse reactions | 3OWL53L36A |
| Osmitrol | MANNITOL | Baxter Healthcare Company | 0d914965-7001-45cb-ba51-d7c5964b05bc | 2025-08-26 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | Henry Schein, Inc. | e2444db1-9dfe-451f-a33c-9b00786464d2 | 2025-05-20 | Warnings, Adverse reactions | 3OWL53L36A |
| MANNITOL | MANNITOL | HF Acquisition Co LLC, DBA HealthFirst | 999ce711-2d5b-0d7d-e053-2995a90a2689 | 2024-01-27 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | B. Braun Medical Inc. | d12cc802-b538-4065-a264-f474ff3b3043 | 2023-08-15 | Warnings, Adverse reactions | 3OWL53L36A |
| Mannitol | MANNITOL | Fresenius Kabi USA, LLC | c395e13d-6ea1-4104-8b37-669cfb982f04 | 2023-03-16 | Warnings, Adverse reactions | 3OWL53L36A |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.